Myasthenia Gravis, Generalized

Immunology·MeSH: Myasthenia Gravis

Prevalence

20.0 / 100K

Incidence

1.7 / 100K/yr

8 drugs in development·6 companies·7 clinical trials

Drug Pipeline by Phase

Phase 3(5)

Drug	Company
claseprubart	Dianthus Therapeutics, Inc. /DE/ (DNTH)
descartes-08	Cartesian Therapeutics, Inc. (RNAC)
DNTH103	Dianthus Therapeutics, Inc. /DE/ (DNTH)
zilucoplan	RA PHARMACEUTICALS, INC. (RARX)
zilucoplan xr	RA PHARMACEUTICALS, INC. (RARX)

Phase 1(1)

Drug	Company
povetacicept	VERTEX PHARMACEUTICALS INC / MA (VRTX)

Phase 1/Phase 2(1)

Drug	Company
aritinercept	Aurinia Pharmaceuticals Inc. (AUPH)

Phase 4(1)

Drug	Company
Ravulizumab	ASTRAZENECA PLC (AZN)

BioSniper tracks 8 drugs in development for Myasthenia Gravis, Generalized across 6 companies.

There are 7 clinical trials targeting Myasthenia Gravis, Generalized tracked by BioSniper.

The estimated prevalence of Myasthenia Gravis, Generalized is approximately 20.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.